Abstract
Malignant gliomas are common primary tumors of the central nervous system, characterized by aggressive cell proliferation, diffuse infiltration and resistance to conventional therapy. Glioblastoma (former Glioblastoma multiforme, GBM), grade IV astrocytoma, is the most aggressive tumor, with a median survival of around 14 months. New therapies against this devastating and invariably fatal disease are needed. Stem-like cell populations have been identified in a number of malignancies including glioblastoma. These rare stem cells (called also glioma-initiating cells) are believed to be responsible not only for tumor initiation and progression but also resistance to therapeutic agents and tumor recurrence. Recently, the population of cells within glioblastoma with stem-like properties has gained increasing attention as a target to refine treatment strategies. This chapter aims to summarize the recent data regarding isolation, biology and mechanisms of resistance of glioblastoma stem-like cells to therapy.
Keywords: Glioblastoma, glioma-initiating cells (GIC), glioma stem cells (GSC), functional characteristics, isolation, markers, therapeutic resistance.
Current Signal Transduction Therapy
Title:Glioblastoma Stem-Like Cells – Isolation, Biology and Mechanisms of Chemotherapy Resistance
Volume: 8 Issue: 3
Author(s): Iwona Anna Ciechomska, Marta Kocyk and Bozena Kaminska
Affiliation:
Keywords: Glioblastoma, glioma-initiating cells (GIC), glioma stem cells (GSC), functional characteristics, isolation, markers, therapeutic resistance.
Abstract: Malignant gliomas are common primary tumors of the central nervous system, characterized by aggressive cell proliferation, diffuse infiltration and resistance to conventional therapy. Glioblastoma (former Glioblastoma multiforme, GBM), grade IV astrocytoma, is the most aggressive tumor, with a median survival of around 14 months. New therapies against this devastating and invariably fatal disease are needed. Stem-like cell populations have been identified in a number of malignancies including glioblastoma. These rare stem cells (called also glioma-initiating cells) are believed to be responsible not only for tumor initiation and progression but also resistance to therapeutic agents and tumor recurrence. Recently, the population of cells within glioblastoma with stem-like properties has gained increasing attention as a target to refine treatment strategies. This chapter aims to summarize the recent data regarding isolation, biology and mechanisms of resistance of glioblastoma stem-like cells to therapy.
Export Options
About this article
Cite this article as:
Ciechomska Anna Iwona, Kocyk Marta and Kaminska Bozena, Glioblastoma Stem-Like Cells – Isolation, Biology and Mechanisms of Chemotherapy Resistance, Current Signal Transduction Therapy 2013; 8 (3) . https://dx.doi.org/10.2174/1574362409666140206223501
DOI https://dx.doi.org/10.2174/1574362409666140206223501 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypericin - A New Antiviral and Antitumor Photosensitizer: Mechanism of Action and Interaction with Biological Macromolecules
Current Drug Targets An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs
Current Topics in Medicinal Chemistry Combined Chemotherapy or Biotherapy with Jasmonates: Targeting Energy Metabolism for Cancer Treatment
Current Pharmaceutical Biotechnology One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology Interleukin-7: a key Mediator in T Cell-driven Autoimmunity, Inflammation, and Tissue Destruction
Current Pharmaceutical Design Recent Progress in Delivery of Therapeutic and Imaging Agents Utilizing Organic-Inorganic Hybrid Nanoparticles
Current Drug Delivery Atypical PKCι as Target for Glioblastoma Therapy
Current Cancer Drug Targets Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism Near Infrared Receptor-Targeted Nanoprobes for Early Diagnosis of Cancers
Current Medicinal Chemistry Application of Nanotechnology in the Diagnosis and Therapy of Hepatocellular Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Low Concentration of Caffeine Inhibits the Progression of the Hepatocellular Carcinoma <i>via Akt</i> Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
Recent Patents on Anti-Cancer Drug Discovery Systems Cytogenomics: Are We Ready Yet?
Current Genomics Copper Compounds in Anticancer Strategies
Current Medicinal Chemistry Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry Medical Applications of Implantable Drug Delivery Microdevices Based on MEMS (Micro-Electro-Mechanical-Systems)
Current Pharmaceutical Biotechnology Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry BRCA-FA Pathway as a Target for Anti-Tumor Drugs
Anti-Cancer Agents in Medicinal Chemistry NAD+ Metabolism and NAD+-Dependent Enzymes: Promising Therapeutic Targets for Neurological Diseases
Current Drug Targets Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer
Current Pharmaceutical Design